Literature DB >> 32005775

18F-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders.

Filipe M Montes de Jesus1, Andor W J M Glaudemans2, Wim J Tissing3, Rudi A J O Dierckx2, Stefano Rosati4, Arjan Diepstra4, Walter Noordzij2, Thomas C Kwee5.   

Abstract

We aimed to evaluate the diagnostic performance of 18F-FDG PET/CT for the detection of posttransplantation lymphoproliferative disorder (PTLD) in a pediatric population and explore its feasibility during response assessment.
Methods: This retrospective study included 28 pediatric transplant recipients who underwent a total of 32 18F-FDG PET/CT scans due to clinical suspicion of PTLD within an 8-y period. Pathology reports and 2 y of follow-up were used as the reference standard. Twenty-one response assessment 18F-FDG PET/CT scans were reevaluated according to the Lugano criteria.
Results: The diagnosis of PTLD was established in 14 patients (49%). Sensitivity, specificity, positive predictive value, and negative predictive value of 18F-FDG PET/CT for the detection of PTLD in children with a clinical suspicion of this disease were 50% (7/14), 100% (18/18), 100% (7/7), and 72% (18/25), respectively. False-negative results occurred in patients with PTLD in the Waldeyer's ring, cervical lymph nodes, or small bowel with either nondestructive or polymorphic PTLD. Two of 5 interim 18F-FDG PET/CT scans and 3 of 9 end-of-treatment 18F-FDG PET/CT scans were false-positive.
Conclusion: 18F-FDG PET/CT had good specificity and positive predictive value but low to moderate sensitivity and negative predictive value for the detection of PTLD in a 28-pediatric-patient cohort with a clinical suspicion of this disease. False-negative results were confirmed in the Waldeyer's ring, cervical lymph nodes, and small bowel with either nondestructive or polymorphic PTLD subtypes. 18F-FDG PET/CT appears to have a limited role in the response assessment setting of pediatric PTLD, given the observed high proportions of false-positives both at interim and at end-of-treatment evaluations.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-FDG PET/CT; 18F-fluoro-d-deoxyglucose PET; diagnosis; pediatric; posttransplant lymphoproliferative disorder

Year:  2020        PMID: 32005775     DOI: 10.2967/jnumed.119.239624

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  2 in total

1.  Is 18F-FDG PET/CT Effective in Identifying True Residual Disease After Treatment of Pediatric PTLD?

Authors:  Batool El-Atoum; Mark Ebert; Brian Bucher; Zeinab Afify
Journal:  J Nucl Med       Date:  2021-05-14       Impact factor: 11.082

2.  Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT.

Authors:  Felipe Montes de Jesus; V Vergote; W Noordzij; D Dierickx; R A J O Dierckx; A Diepstra; T Tousseyn; O Gheysens; T C Kwee; C M Deroose; A W J M Glaudemans
Journal:  J Clin Med       Date:  2021-01-19       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.